SIGLEC1 and neoplasm: By demonstrating that SMLR1 is upregulated in CRLM and interacts with tumor-associated macrophages (TAMs) via MRC1 (CD206) and SIGLEC1 (CD169), this research unveils a novel mechanism of immune evasion and tumor progression.